Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons dr. W.W.H. Roeloffzen

Publicaties

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA

Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years

A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma

Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse

Desensitisatie als behandeloptie bij geneesmiddelenhypersensitiviteit

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijn

Meer informatie over de Sustainable Development Goals.